Bristol's Abilify gets expanded FDA approval

02/28/2008 | Bloomberg

Abilify, an antipsychotic drug from Bristol-Myers Squibb Co., has received additional FDA clearance for the treatment of bipolar disorder in children 10 years and older. The company currently markets the drug for schizophrenia patients aged 13 and up and adults with bipolar disorder and major depression.

View Full Article in:

Bloomberg

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Senior Director, Research
America's Health Insurance Plans (AHIP)
Washington, DC
Stop Loss Sales Executive
Blue Cross Blue Shield of MA
Boston, MA
Regional Director, Southeastern Region - State Affairs
America's Health Insurance Plans (AHIP)
Washington, DC
Field Representative-Oklahoma and Kansas
National Rural Electric Cooperative Association (NRECA)
Multiple Locations, SL_Multiple Locations
Market Intelligence Manager
Olympus Corporation of the Americas
Southborough, MA